142 related articles for article (PubMed ID: 29108753)
1. Docking based design of diastereoisomeric MTCA as GPIIb/IIIa receptor inhibitor.
Wang X; Wang Y; Wu J; Gui L; Zhang X; Zheng M; Wang Y; Zhao S; Li Z; Zhao M; Peng S
Bioorg Med Chem Lett; 2017 Dec; 27(23):5114-5118. PubMed ID: 29108753
[TBL] [Abstract][Full Text] [Related]
2. Heptapeptide-based modification leading to enhancing the action of MTCA on activated platelets, P-selectin, GPIIb/IIIa.
Li Z; Huang F; Wu J; Gui L; Zhang X; Wang Y; Zhao S; Wang X; Peng S; Zhao M
Future Med Chem; 2018 Aug; 10(16):1957-1970. PubMed ID: 29973078
[TBL] [Abstract][Full Text] [Related]
3. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
Armstrong PC; Peter K
Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
[TBL] [Abstract][Full Text] [Related]
4. Design and development of ICCA as a dual inhibitor of GPIIb/IIIa and P-selectin receptors.
Chen H; Lu A; Zhang X; Gui L; Wang Y; Wu J; Feng H; Peng S; Zhao M
Drug Des Devel Ther; 2018; 12():2097-2110. PubMed ID: 30022809
[TBL] [Abstract][Full Text] [Related]
5. The application of tetrahydroisoquinoline-3-carbonyl-TARGD(F)F as an anti-thrombotic agent having dual mechanisms of action.
Yang G; Zhu H; Zhao M; Wu J; Wang Y; Wang Y; Zheng M; Chen M; Liu J; Peng S
Mol Biosyst; 2012 Oct; 8(10):2672-9. PubMed ID: 22801714
[TBL] [Abstract][Full Text] [Related]
6. (1R,3S)-THCCA-Asn: To show the discovery of selective inhibitor of thrombin by successfully combining virtual screening and biological assay.
Zhang X; Yang Y; Wang Y; Wu J; Fang Q; Wang Y; Zhao M; Peng S
Eur J Med Chem; 2022 Nov; 242():114681. PubMed ID: 36001936
[TBL] [Abstract][Full Text] [Related]
7. Targeting the platelet integrin GPIIb/IIIa.
Hagemeyer CE; Peter K
Curr Pharm Des; 2010; 16(37):4119-33. PubMed ID: 21247395
[TBL] [Abstract][Full Text] [Related]
8. Nano-scaled MTCA-KKV: for targeting thrombus, releasing pharmacophores, inhibiting thrombosis and dissolving blood clots in vivo.
Zhao S; Li Z; Huang F; Wu J; Gui L; Zhang X; Wang Y; Wang X; Peng S; Zhao M
Int J Nanomedicine; 2019; 14():4817-4831. PubMed ID: 31308660
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and evaluation of 1,4-benzodioxine derivatives as novel platelet aggregation inhibitors.
Xie Z; Zhao L; Ding X; Kong Y; Li Z
Future Med Chem; 2018 Feb; 10(4):367-378. PubMed ID: 29380625
[TBL] [Abstract][Full Text] [Related]
10. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
[TBL] [Abstract][Full Text] [Related]
11. FcgammaRII mediates platelet aggregation caused by disintegrins and GPIIb/IIIa monoclonal antibody, AP2.
Huang TF; Chang CH; Ho PL; Chung CH
Exp Hematol; 2008 Dec; 36(12):1704-13. PubMed ID: 18809237
[TBL] [Abstract][Full Text] [Related]
12. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
Quinn MJ; Cox D; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104
[TBL] [Abstract][Full Text] [Related]
14. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
[TBL] [Abstract][Full Text] [Related]
15. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
16. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
17. The anti-platelet approach targeting the fibrinogen ligand of the GPIIB/IIIa receptor.
Tsikaris V
J Pept Sci; 2004 Oct; 10(10):589-602. PubMed ID: 15526708
[TBL] [Abstract][Full Text] [Related]
18. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
Schwarz M; Meade G; Stoll P; Ylanne J; Bassler N; Chen YC; Hagemeyer CE; Ahrens I; Moran N; Kenny D; Fitzgerald D; Bode C; Peter K
Circ Res; 2006 Jul; 99(1):25-33. PubMed ID: 16778135
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy.
Lippi G; Montagnana M; Danese E; Favaloro EJ; Franchini M
Biomark Med; 2011 Feb; 5(1):63-70. PubMed ID: 21319966
[TBL] [Abstract][Full Text] [Related]
20. Oral GPIIb/IIIa antagonists: what went wrong?
Cox D
Curr Pharm Des; 2004; 10(14):1587-96. PubMed ID: 15134557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
